Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.60 |
| ▸ | HRH1 | P35367 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | HRH2 | P25021 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.60 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27491763 | 0.93 | CHRM3 (0.51) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL2166483 | 0.89 | CHRM2 (0.62) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL8432689 | 0.89 | CHRM3 (0.62) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL9922432 | 0.89 | CHRM2 (0.62) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL11295361 | 0.89 | CHRM3 (0.62) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL2166587 | 0.88 | CHRM2 (0.68) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL2168512 | 0.88 | CHRM2 (0.68) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL7558351 | 0.87 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL5178337 | 0.87 | CHRM3 (0.61) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL2166958 | 0.86 | CHRM3 (0.58) | CHRM3CHRM2CHRM1CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG | 2004-09-23 | — | — | US | claimed |
| US-6713464-B1 | ANTIMUSCARINIC AGENTS WITH SUPERIOR PHARMACOKINETICS | SCHWARZ PHARMA AG (DE) | 2004-03-30 | — | — | US | claimed |
| EP-1254890-A1 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2002-11-06 | — | — | EP | claimed |
| EP-1077912-B1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2002-07-03 | — | — | EP | claimed |
| EP-1077912-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058478-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 1999-11-18 | — | — | WO | claimed |
| US-8338478-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-7985772-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2011-07-26 | — | — | US | disclosed |
| US-7855230-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2010-12-21 | — | — | US | disclosed |
| US-20100256231-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | UCB PHARMA GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20090042981-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-7384980-B2 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2008-06-10 | — | — | US | disclosed |
| US-7230030-B2 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060270738-A1 | Novel derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2006-11-30 | — | — | US | disclosed |
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG | 2004-09-23 | — | — | US | disclosed |
| US-6713464-B1 | ANTIMUSCARINIC AGENTS WITH SUPERIOR PHARMACOKINETICS | SCHWARZ PHARMA AG (DE) | 2004-03-30 | — | — | US | disclosed |
| EP-1254890-A1 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2002-11-06 | — | — | EP | disclosed |
| EP-1077912-B1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2002-07-03 | — | — | EP | disclosed |
| EP-1077912-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058478-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042981-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | ADRB3, TNNI3, ADRB2 | CHRM3 41/4885CHRM2 140/4885CHRM1 263/4885 |
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | ADRB3, ADRA1D, TNNC1 | CHRM3 70/4885CHRM2 136/4885CHRM1 227/4885 |
| US-20060270738-A1 | Novel derivatives of 3,3-diphenylpropylamines | ADRB3, ADRA1D, TNNC1 | CHRM3 70/4885CHRM2 136/4885CHRM1 227/4885 |
| US-20100256231-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | ADRB3, TNNI3, ADRB2 | CHRM3 41/4885CHRM2 140/4885CHRM1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.